Integrin-linked kinase is dispensable for multiple myeloma cell survival

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1165-1171

  Steinbrunn, Torsten ^a   Siegmund, Daniela ^a   Andrulis, Mindaugas ^b   Grella, Evelyn ^a   Kortüm, Martin ^a   Einsele, Hermann ^a   Wajant, Harald ^a   Bargou, Ralf C ^a   Stühmer, Thorsten ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Integrin linked kinase; Multiple myeloma; QLT0267

Indexed keywords

INTEGRIN LINKED KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PYRAZOLE DERIVATIVE; QTL 0267; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AZO COMPOUNDS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RNA, SMALL INTERFERING;

EID: 84864012947     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.005     Document Type: Article

References (28)

1. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
2. Fonseca R., Bergsagel P.L., Drach J., Shaughnessy J., Gutierrez N., Stewart A.K., et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
3. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
4. 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
5. Hannigan G., Troussard A.A., Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005, 5:51-63.
6. Hehlgans S., Haase M., Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 2007, 1775:163-180.
7. Zhang Y., Chen K., Tu Y., Velyvis A., Yang Y., Qin J., et al. Assembly of the PINCH-ILK-CH-ILKBP complex precedes and is essential for localization of each component to cell-matrix adhesion sites. J Cell Sci 2002, 115:4777-4786.
8. Hannigan G.E., McDonald P.C., Walsh M.P., Dedhar S. Integrin-linked kinase: not so 'pseudo' after all. Oncogene 2011, 30:4375-4385.
9. Fukuda K., Knight J.D.R., Piszczek G., Kothary R., Qin J. Biochemical, proteomic, structural, and thermodynamic characterizations of integrin-linked kinase (ILK). J Biol Chem 2011, 286:21886-21895.
10. McDonald P.C., Fielding A.B., Dedhar S. Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci 2008, 121:3121-3132.
11. Sawai H., Okada Y., Funahashi H., Matsuo Y., Takahashi H., Takeyama H., et al. Integrin-linked kinase activity is associated with interleukin-1α-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 2006, 25:3237-3246.
12. Okamura M., Yamaji S., Nagashima Y., Yoshimoto N., Kido Y., Iemoto Y., et al. Prognostic value of integrin β1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007, 38:1081-1091.
13. Hess F., Estrugo D., Fischer A., Belka C., Cordes N. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 2006, 26:1372-1384.
14. Chen P., Shen W.-Z., Karnik P. Suppression of malignant growth of human breast cancer cells by ectopic expression of integrin-linked kinase. Int J Cancer 2004, 111:881-891.
15. Durbin A.D., Somers G.R., Forrester M., Pienkowska M., Hannigan G.E., Malkin D. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009, 119:1558-1570.
16. Mitsiades C.S., Mitsiades N.S., Richardson P.G., Munshi N.C., Anderson K.C. Multiple myeloma. A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007, 101:950-968.
17. Stühmer T., Arts J., Chatterjee M., Borawski J., Wolff A., King P., et al. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. Br J Haematol 2010, 149:529-536.
18. Troussard A.A., McDonald P.C., Wederell E.D., Mawji N.M., Filipenko N.R., Gelmon K.A., et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 2006, 66:393-403.
19. Janz M., Stühmer T., Vassilev L.T., Bargou R.C. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007, 21:772-779.
20. Steinbrunn T., Stühmer T., Gattenlöhner S., Rosenwald A., Mottok A., Unzicker C., et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood 2011, 117:1998-2004.
21. Troussard A.A., Mawji N.M., Ong C., Mui A., St.-Arnaud R., Dedhar S. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 2003, 278:22374-22378.
22. Fulda S., Debatin K.-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
23. Krueger A., Baumann S., Krammer P.H., Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001, 21:8247-8254.
24. Engels I.H., Stepczynska A., Stroh C., Lauber K., Berg C., Schwenzer R., et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000, 19:4563-4573.
25. Wang X., Zhang Z., Yao C. Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs. Med Oncol 2011, 28:1596-1600.
26. Chatterjee M., Stühmer T., Herrmann P., Bommert K., Dörken B., Bargou R.C. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004, 104:3712-3721.
27. Muranyi A.L., Dedhar S., Hogge D.E. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 2009, 37:450-460.
28. Eke I., Leonhardt F., Storch K., Hehlgans S., Cordes N. The small molecule inhibitor QLT0267 radiosensitizes squamous cell carcinoma cells of the head and neck. PLoS One 2009, 4:e6434.